ZA201303049B - Crystalline forms of (s)-2-amino-3-(4-(2- amino-6-((r)-1(4-chloro-2-(3-methyl-1h-pyrazol-1-yl) phenyl)- 2, 2, 2-trifluoroethoxy)pyrimidin-4- yl)phenyl)propanoic acid - Google Patents

Crystalline forms of (s)-2-amino-3-(4-(2- amino-6-((r)-1(4-chloro-2-(3-methyl-1h-pyrazol-1-yl) phenyl)- 2, 2, 2-trifluoroethoxy)pyrimidin-4- yl)phenyl)propanoic acid

Info

Publication number
ZA201303049B
ZA201303049B ZA2013/03049A ZA201303049A ZA201303049B ZA 201303049 B ZA201303049 B ZA 201303049B ZA 2013/03049 A ZA2013/03049 A ZA 2013/03049A ZA 201303049 A ZA201303049 A ZA 201303049A ZA 201303049 B ZA201303049 B ZA 201303049B
Authority
ZA
South Africa
Prior art keywords
phenyl
amino
trifluoroethoxy
pyrazol
pyrimidin
Prior art date
Application number
ZA2013/03049A
Other languages
English (en)
Inventor
Qun Li
Weifeng Hu
Xiaogen Yang
Jiangqiong Zhao
Matthew Mangzhu Zhao
Original Assignee
Lexicon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexicon Pharmaceuticals Inc filed Critical Lexicon Pharmaceuticals Inc
Publication of ZA201303049B publication Critical patent/ZA201303049B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2013/03049A 2010-11-05 2013-04-25 Crystalline forms of (s)-2-amino-3-(4-(2- amino-6-((r)-1(4-chloro-2-(3-methyl-1h-pyrazol-1-yl) phenyl)- 2, 2, 2-trifluoroethoxy)pyrimidin-4- yl)phenyl)propanoic acid ZA201303049B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41042110P 2010-11-05 2010-11-05
PCT/US2011/059107 WO2012061576A1 (en) 2010-11-05 2011-11-03 Crystalline forms of ( s ) - 2 - amino - 3 - (4 - ( 2 - amino - 6 - ( (r) - 1 - (4 - ch loro-2- (3 -methyl- 1h- pyrazol- 1 -yl) phenyl) - 2, 2, 2 - trifluoroethoxy) pyrimidin- 4 - yl) phenyl) propanoic acid

Publications (1)

Publication Number Publication Date
ZA201303049B true ZA201303049B (en) 2014-07-30

Family

ID=45023872

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/03049A ZA201303049B (en) 2010-11-05 2013-04-25 Crystalline forms of (s)-2-amino-3-(4-(2- amino-6-((r)-1(4-chloro-2-(3-methyl-1h-pyrazol-1-yl) phenyl)- 2, 2, 2-trifluoroethoxy)pyrimidin-4- yl)phenyl)propanoic acid

Country Status (15)

Country Link
US (1) US8772483B2 (enExample)
EP (1) EP2635569A1 (enExample)
JP (1) JP2013541589A (enExample)
KR (1) KR20130141572A (enExample)
CN (1) CN103228648A (enExample)
AR (1) AR083755A1 (enExample)
AU (1) AU2011323302A1 (enExample)
BR (1) BR112013011015A2 (enExample)
CA (1) CA2816963A1 (enExample)
MX (1) MX2013004921A (enExample)
RU (1) RU2013125756A (enExample)
SG (1) SG189535A1 (enExample)
TW (1) TW201245183A (enExample)
WO (1) WO2012061576A1 (enExample)
ZA (1) ZA201303049B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120077831A1 (en) * 2009-11-23 2012-03-29 Philip Manton Brown Methods and assays for the treatment of irritable bowel syndrome
CN102711757A (zh) * 2009-11-23 2012-10-03 莱西肯医药有限公司 用于治疗肠易激综合征的方法和分析法
UA119247C2 (uk) 2013-09-06 2019-05-27 РОЙВЕНТ САЙЕНСИЗ ҐмбГ Спіроциклічні сполуки як інгібітори триптофангідроксилази
US9611201B2 (en) 2015-03-05 2017-04-04 Karos Pharmaceuticals, Inc. Processes for preparing (R)-1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanol and 1-(5-chloro-[1,1′-biphenyl]-2-yl)-2,2,2-trifluoroethanone
CN109180650A (zh) * 2018-08-28 2019-01-11 湖南华腾制药有限公司 一种氘代色氨酸羟化酶抑制剂的晶型
AU2019382168A1 (en) * 2018-11-16 2021-06-03 Altavant Sciences Gmbh A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089335A2 (en) * 2005-12-29 2007-08-09 Lexicon Pharmaceutical Inc. Multicyclic amino acid derivatives and methods of their use
US7897763B2 (en) 2005-12-29 2011-03-01 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
US7855291B2 (en) 2005-12-29 2010-12-21 Lexicon Pharmaceuticals, Inc. Process for the preparation of substituted phenylalanines
UA99270C2 (en) * 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
RU2493156C2 (ru) 2007-08-24 2013-09-20 Лексикон Фармасьютикалз, Инк. Способы получения соединений на основе 4-фенил-6-(2,2,2-трифтор-1-фенилэтокси)пиримидина

Also Published As

Publication number Publication date
CN103228648A (zh) 2013-07-31
AU2011323302A1 (en) 2013-05-30
MX2013004921A (es) 2013-06-28
BR112013011015A2 (pt) 2016-08-23
US20120122904A1 (en) 2012-05-17
WO2012061576A1 (en) 2012-05-10
KR20130141572A (ko) 2013-12-26
SG189535A1 (en) 2013-06-28
RU2013125756A (ru) 2014-12-10
US8772483B2 (en) 2014-07-08
CA2816963A1 (en) 2012-05-10
JP2013541589A (ja) 2013-11-14
AR083755A1 (es) 2013-03-20
TW201245183A (en) 2012-11-16
EP2635569A1 (en) 2013-09-11

Similar Documents

Publication Publication Date Title
IL242285A0 (en) 4-Methoxy-n3-(pyrimidin-2-yl)benzene-3, 1-converted diamine compounds and their salts
HRP20190012T1 (hr) Novi fuzionirani pirimidin derivati za inhibiciju aktivnosti tirozin kinaze
PL3415517T3 (pl) Postać krystaliczna 1-(4-1-(2,6-difluorobenzylo)-5-dimetyloaminometylo-3-(6-metoksypirydazyn-3-ylo)-2,4-diokso-1,2,3,4-tetrahydrotieno(2,3-d)-pirymidyn-6-ylo)fenylo)-3-metoksymocznika
AP3902A (en) Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
IL220155B (en) History of 2, 4-(phenyl-amine-)di-converted pyrimidines for use as kinase inhibitors
ZA201108541B (en) 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1hpyrazol-1yl]octane-or heptane-nitrile as jak inhibitors
IL231958B (en) Solid dosage forms of (s)-ethyl-2-amino-3-(4-(2-amino-6(r)-1-(4-chloro-2-(3-methyl-h1-pyrazol-1-yl )-2,2,2-trifluoroethoxy)pyrimidine-4-yl(phenyl)propanoate
IL232041A0 (en) Immediate-release oral formulations for metabolised quinazolinones
DK2797581T3 (da) Formuleringer af (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methansulfonylethyl]-4-acetylaminoisoindolin-1,3-dion
ITMI20110464A1 (it) Nuovo procedimento per la preparazione di erlotinib
LT3395796T (lt) (3s,3s') 4,4'-disulfandiil-bis-(3-aminobutan-1-sulfonrūgšties) kristalinė trihidrato forma
IT1395118B1 (it) Procedimento per la preparazione di dexlansoprazolo cristallino
ZA201105124B (en) Process for the preparation of rosuvastatin salts
HUP1000638A2 (en) Process for preparation of rosuvastatin salts
IL232693B (en) Crystal structures of 2-(2-methylamino-pyrimidin-4-yl)-1h-1indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl] -Amide
ZA201302996B (en) Solid forms of 3-(4-(aminomethyl)-1-(5-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate
TH148782B (th) รูปแบบปริมาณขนาดยาชนิดแข็งที่ให้ของ (S)-เอทธิล-2-อะมิโน-3-(4-(2-อะมิโน-6-((R)-1-(4-คลอโร-2-(3-เมทธิล-1H-ไพราซอล-1-อิล)ฟีนิล)-2,2,2-ไตรฟลูออโรเอทธอกซี) ไพริมิดิน-4-อิล)ฟีนิล)โพรพาโนเอต ((S)-ethyl-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-y1)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoate)
HK1188394A (en) Formulations of phenyl uracil compounds
SI2709988T1 (sl) Postopek za pripravo (4,6-bis-dimetilamino-2- (4- (4- trifluorometilbenzoil-amino)benzil) primidin-5-il) ocetne kisline
HK1167593A (en) Process for the preparation of rosuvastatin salts